Clinical Trial Results:
Open, Randomised, Comparative, Multicentre Study of the Immunogenicity and Safety of Concomitant versus Separate administration of a combined measles, mumps, rubella and varicella live vaccine (ProQuad®) and a Booster dose of Infanrix® hexa in Healthy Children 12 to 23 months of age
Summary
|
|
EudraCT number |
2006-004129-27 |
Trial protocol |
DE IT |
Global end of trial date |
27 Mar 2008
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
27 Apr 2016
|
First version publication date |
22 Jul 2015
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
X06-MMRV-302
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT00432042 | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
Sanofi Pasteur MSD S.N.C.
|
||
Sponsor organisation address |
162 avenue Jean Jaurès - CS 50712, Lyon Cedex 07, France, 69367
|
||
Public contact |
Clinical Trials Disclosure, Sanofi Pasteur MSD S.N.C., ClinicalTrialsDisclosure@spmsd.com
|
||
Scientific contact |
Clinical Trials Disclosure, Sanofi Pasteur MSD S.N.C., ClinicalTrialsDisclosure@spmsd.com
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
Yes
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
27 Mar 2008
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
27 Mar 2008
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
27 Mar 2008
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
To demonstrate that ProQuad® can be administered concomitantly with a booster dose of Infanrix® hexa to healthy children of 12 to 23 months of age without impairing neither the antibody response rates to measles, mumps, rubella, varicella, hepatitis B, and Haemophilus influenzae type b, or to the 3 pertussis antibody titres measured at 42 days following vaccination.
|
||
Protection of trial subjects |
Healthy subjects with prior known sensitivity/allergy to any component of the vaccine including neomycin, sorbitol or gelatine were excluded.
Vaccines were administered by qualified study personnel.
After each vaccination, subjects were kept under observation for at least 20 minutes to ensure their safety.
Appropriate medical treatment and supervision were always readily available in case of a rare anaphylactic reaction following the administration of the vaccine.
|
||
Background therapy |
# For Italy, primary vaccination with the combined diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and Haemophilus influenzae type b vaccine Infanrix hexa as a 2-dose schedule, with receipt of the 2nd dose ≥6 months prior to inclusion. # For Germany, primary vaccination with the combined diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and Haemophilus influenzae type b vaccine Infanrix hexa as a 3-dose schedule, with receipt of the 3rd dose ≥6 months prior to inclusion. | ||
Evidence for comparator |
The immunisation schedule of hexavalent vaccines consists of a primary series followed by a booster dose given at the same age as ProQuad. The rationale of the study was to generate immunogenicity and safety data for ProQuad when administered concomitantly either with the 3rd dose of Infanrix hexa (Italian schedule) or with the 4th dose of Infanrix hexa (German schedule) given in the 2nd year of life. Therefore, concomitant administration of ProQuad and Infanrix hexa was compared to administration of each of these vaccines alone. | ||
Actual start date of recruitment |
12 Jan 2007
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Germany: 728
|
||
Country: Number of subjects enrolled |
Italy: 227
|
||
Worldwide total number of subjects |
955
|
||
EEA total number of subjects |
955
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
954
|
||
Children (2-11 years) |
1
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
0
|
||
From 65 to 84 years |
0
|
||
85 years and over |
0
|
|
|||||||||||||||||||||||||||||
Recruitment
|
|||||||||||||||||||||||||||||
Recruitment details |
Study subjects were enrolled between 12 January 2007 and 13 February 2008 in 51 active centres: 6 vaccination centres in Italy, and 45 private paediatricians in Germany. | ||||||||||||||||||||||||||||
Pre-assignment
|
|||||||||||||||||||||||||||||
Screening details |
963 subjects were screened. 955 subjects were randomised (14 subjects randomised in 1 centre in Germany were excluded from analyses due to a major Good Clinical Practice (GCP) non compliance (non reliability of vaccination history)). 952 subjects received at least 1 vaccine dose. 945 subjects completed the study. | ||||||||||||||||||||||||||||
Period 1
|
|||||||||||||||||||||||||||||
Period 1 title |
Overall trial (overall period)
|
||||||||||||||||||||||||||||
Is this the baseline period? |
Yes | ||||||||||||||||||||||||||||
Allocation method |
Randomised - controlled
|
||||||||||||||||||||||||||||
Blinding used |
Not blinded | ||||||||||||||||||||||||||||
Blinding implementation details |
Not applicable as this study was open-label.
For immunogenicity data, serology tests were performed by laboratory staffs who were blinded to which vaccine each subject received.
|
||||||||||||||||||||||||||||
Arms
|
|||||||||||||||||||||||||||||
Are arms mutually exclusive |
Yes
|
||||||||||||||||||||||||||||
Arm title
|
Group 1: ProQuad + Infanrix hexa | ||||||||||||||||||||||||||||
Arm description |
# Subjects received ProQuad (measles, mumps, rubella and varicella (live attenuated)) vaccine dose 1 by subcutaneous route concomitantly with Infanrix hexa (DTaP-HBV-IPV-Hib = Diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inactivated), and Haemophilus influenzae type b conjugate vaccine (adsorbed)) booster dose by intramuscular route at 12-23 months of age. # Subjects were blood sampled at (i) Day -7 (D-7) to D0 before vaccination = pre-vaccination, and (ii) 6 weeks (D42 to D56) after vaccination = post-vaccination. | ||||||||||||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||||||||||||
Investigational medicinal product name |
ProQuad®
|
||||||||||||||||||||||||||||
Investigational medicinal product code |
MMRV
|
||||||||||||||||||||||||||||
Other name |
ProQuad
|
||||||||||||||||||||||||||||
Pharmaceutical forms |
Powder and solvent for suspension for injection
|
||||||||||||||||||||||||||||
Routes of administration |
Subcutaneous use
|
||||||||||||||||||||||||||||
Dosage and administration details |
0.5 mL, subcutaneous route (deltoid region), 1 dose at 12-23 months of age.
ProQuad had to be administered in the contralateral arm than the one for Infanrix hexa.
|
||||||||||||||||||||||||||||
Investigational medicinal product name |
Infanrix® hexa
|
||||||||||||||||||||||||||||
Investigational medicinal product code |
DTaP-HBs-IPV//Hib
|
||||||||||||||||||||||||||||
Other name |
Infanrix hexa
|
||||||||||||||||||||||||||||
Pharmaceutical forms |
Powder and suspension for suspension for injection
|
||||||||||||||||||||||||||||
Routes of administration |
Intramuscular use
|
||||||||||||||||||||||||||||
Dosage and administration details |
0.5 mL, intramuscular route (deltoid region), 1 dose at 12-23 months of age.
Infanrix hexa had to be administered in the contralateral arm than the one for ProQuad.
|
||||||||||||||||||||||||||||
Arm title
|
Group 2: ProQuad | ||||||||||||||||||||||||||||
Arm description |
# Subjects received ProQuad (measles, mumps, rubella and varicella (live attenuated)) vaccine dose 1 by subcutaneous route at 12-23 months of age. # Subjects were blood sampled at (i) Day -7 (D-7) to D0 before vaccination = pre-vaccination, and (ii) 6 weeks (D42 to D56) after vaccination = post-vaccination. | ||||||||||||||||||||||||||||
Arm type |
Active comparator | ||||||||||||||||||||||||||||
Investigational medicinal product name |
ProQuad®
|
||||||||||||||||||||||||||||
Investigational medicinal product code |
MMRV
|
||||||||||||||||||||||||||||
Other name |
ProQuad
|
||||||||||||||||||||||||||||
Pharmaceutical forms |
Powder and solvent for suspension for injection
|
||||||||||||||||||||||||||||
Routes of administration |
Subcutaneous use
|
||||||||||||||||||||||||||||
Dosage and administration details |
0.5 mL, subcutaneous route (deltoid region), 1 dose at 12-23 months of age.
|
||||||||||||||||||||||||||||
Arm title
|
Group 3: Infanrix hexa | ||||||||||||||||||||||||||||
Arm description |
# Subjects received Infanrix hexa (DTaP-HBV-IPV-Hib = Diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inactivated), and Haemophilus influenzae type b conjugate vaccine (adsorbed)) booster dose by intramuscular route at 12-23 months of age. # Subjects were blood sampled at (i) Day -7 (D-7) to D0 before vaccination = pre-vaccination, and (ii) 6 weeks (D42 to D56) after vaccination = post-vaccination. | ||||||||||||||||||||||||||||
Arm type |
Active comparator | ||||||||||||||||||||||||||||
Investigational medicinal product name |
Infanrix® hexa
|
||||||||||||||||||||||||||||
Investigational medicinal product code |
DTaP-HBs-IPV//Hib
|
||||||||||||||||||||||||||||
Other name |
Infanrix hexa
|
||||||||||||||||||||||||||||
Pharmaceutical forms |
Powder and suspension for suspension for injection
|
||||||||||||||||||||||||||||
Routes of administration |
Intramuscular use
|
||||||||||||||||||||||||||||
Dosage and administration details |
0.5 mL, intramuscular route (deltoid region), 1 dose at 12-23 months of age.
|
||||||||||||||||||||||||||||
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Group 1: ProQuad + Infanrix hexa
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
# Subjects received ProQuad (measles, mumps, rubella and varicella (live attenuated)) vaccine dose 1 by subcutaneous route concomitantly with Infanrix hexa (DTaP-HBV-IPV-Hib = Diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inactivated), and Haemophilus influenzae type b conjugate vaccine (adsorbed)) booster dose by intramuscular route at 12-23 months of age. # Subjects were blood sampled at (i) Day -7 (D-7) to D0 before vaccination = pre-vaccination, and (ii) 6 weeks (D42 to D56) after vaccination = post-vaccination. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Group 2: ProQuad
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
# Subjects received ProQuad (measles, mumps, rubella and varicella (live attenuated)) vaccine dose 1 by subcutaneous route at 12-23 months of age. # Subjects were blood sampled at (i) Day -7 (D-7) to D0 before vaccination = pre-vaccination, and (ii) 6 weeks (D42 to D56) after vaccination = post-vaccination. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Group 3: Infanrix hexa
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
# Subjects received Infanrix hexa (DTaP-HBV-IPV-Hib = Diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inactivated), and Haemophilus influenzae type b conjugate vaccine (adsorbed)) booster dose by intramuscular route at 12-23 months of age. # Subjects were blood sampled at (i) Day -7 (D-7) to D0 before vaccination = pre-vaccination, and (ii) 6 weeks (D42 to D56) after vaccination = post-vaccination. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Group 1: ProQuad + Infanrix hexa
|
||
Reporting group description |
# Subjects received ProQuad (measles, mumps, rubella and varicella (live attenuated)) vaccine dose 1 by subcutaneous route concomitantly with Infanrix hexa (DTaP-HBV-IPV-Hib = Diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inactivated), and Haemophilus influenzae type b conjugate vaccine (adsorbed)) booster dose by intramuscular route at 12-23 months of age. # Subjects were blood sampled at (i) Day -7 (D-7) to D0 before vaccination = pre-vaccination, and (ii) 6 weeks (D42 to D56) after vaccination = post-vaccination. | ||
Reporting group title |
Group 2: ProQuad
|
||
Reporting group description |
# Subjects received ProQuad (measles, mumps, rubella and varicella (live attenuated)) vaccine dose 1 by subcutaneous route at 12-23 months of age. # Subjects were blood sampled at (i) Day -7 (D-7) to D0 before vaccination = pre-vaccination, and (ii) 6 weeks (D42 to D56) after vaccination = post-vaccination. | ||
Reporting group title |
Group 3: Infanrix hexa
|
||
Reporting group description |
# Subjects received Infanrix hexa (DTaP-HBV-IPV-Hib = Diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inactivated), and Haemophilus influenzae type b conjugate vaccine (adsorbed)) booster dose by intramuscular route at 12-23 months of age. # Subjects were blood sampled at (i) Day -7 (D-7) to D0 before vaccination = pre-vaccination, and (ii) 6 weeks (D42 to D56) after vaccination = post-vaccination. |
|
|||||||||||||||||||||||||
End point title |
Antibody (Ab) response rates to Measles, Mumps, Rubella, and Varicella 6 weeks after ProQuad dose 1, administered concomitantly or not with Infanrix hexa booster dose (Group 1 vs Group 2) [1] | ||||||||||||||||||||||||
End point description |
Percentage of subjects with an Ab titre ≥255 mIU/mL for Measles, ≥10 ELISA Ab units/mL for Mumps, ≥10 IU/mL for Rubella, and ≥5 gpELISA units/mL for Varicella 6 weeks after ProQuad dose 1, administered concomitantly or not with Infanrix hexa booster dose.
All Ab titres were measured by Enzyme-Linked Immunosorbent Assay (ELISA), except Ab to Varicella determined by glycoprotein ELISA (gpELISA).
Analysis was done on the Antigen-Specific Per Protocol Set (PPS), i.e. all randomised subjects initially seronegative for those antigens (Measles Ab titre <255 mIU/mL, Mumps Ab titre <10 ELISA Ab units/mL, Rubella Ab titre <10 IU/mL, and Varicella Ab titre <1.25 gpELISA units/mL) excluding subjects with protocol violations which may interfere with the immunogenicity evaluation.
Note: (N=***, ***) represents the number of assessed subjects in the “ProQuad + Infanrix hexa” and “ProQuad” groups, respectively.
|
||||||||||||||||||||||||
End point type |
Primary
|
||||||||||||||||||||||||
End point timeframe |
6 weeks after ProQuad dose 1, administered concomitantly or not with Infanrix hexa booster dose.
|
||||||||||||||||||||||||
Notes [1] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: The objective of this endpoint was to evaluate the antibody response rates to Measles, Mumps, Rubella, and Varicella 6 weeks after ProQuad dose 1, administered concomitantly or not with Infanrix hexa booster dose. So this endpoint did not concern subjects of the "Infanrix hexa" arm. |
|||||||||||||||||||||||||
|
|||||||||||||||||||||||||
Statistical analysis title |
Non-inferiority for Measles | ||||||||||||||||||||||||
Statistical analysis description |
The estimates of the differences between Group 1 (ProQuad + Infanrix hexa) & Group 2 (ProQuad) response rates were calculated with their 2-sided 95% confidence interval (CI). If the lower bounds of the 95% CI were greater than the non-inferiority margin, it was concluded that Group 1 response rates were non-inferior to Group 2 response rates.
Statistical analysis was based on the Miettinen & Nurminen method with stratification by region.
Analysis was done on the Antigen-specific PPS.
|
||||||||||||||||||||||||
Comparison groups |
Group 1: ProQuad + Infanrix hexa v Group 2: ProQuad
|
||||||||||||||||||||||||
Number of subjects included in analysis |
646
|
||||||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||||||
Analysis type |
non-inferiority [2] | ||||||||||||||||||||||||
Method |
|||||||||||||||||||||||||
Parameter type |
Difference in percentage of subjects | ||||||||||||||||||||||||
Point estimate |
1.14
|
||||||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||||||
level |
95% | ||||||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||||||
lower limit |
-1.62 | ||||||||||||||||||||||||
upper limit |
4.82 | ||||||||||||||||||||||||
Notes [2] - For Measles: # Antigen-specific PPS, N=421, 215 (Groups 1 & 2) # Response rate based on Ab titre ≥255 mIU/mL # Non-inferiority margin, -10%. |
|||||||||||||||||||||||||
Statistical analysis title |
Non-inferiority for Mumps | ||||||||||||||||||||||||
Statistical analysis description |
The estimates of the differences between Group 1 (ProQuad + Infanrix hexa) & Group 2 (ProQuad) response rates were calculated with their 2-sided 95% confidence interval (CI). If the lower bounds of the 95% CI were greater than the non-inferiority margin, it was concluded that Group 1 response rates were non-inferior to Group 2 response rates.
Statistical analysis was based on the Miettinen & Nurminen method with stratification by region.
Analysis was done on the Antigen-specific PPS.
|
||||||||||||||||||||||||
Comparison groups |
Group 1: ProQuad + Infanrix hexa v Group 2: ProQuad
|
||||||||||||||||||||||||
Number of subjects included in analysis |
646
|
||||||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||||||
Analysis type |
non-inferiority [3] | ||||||||||||||||||||||||
Method |
|||||||||||||||||||||||||
Parameter type |
Difference in percentage of subjects | ||||||||||||||||||||||||
Point estimate |
-1.83
|
||||||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||||||
level |
95% | ||||||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||||||
lower limit |
-4.21 | ||||||||||||||||||||||||
upper limit |
1.1 | ||||||||||||||||||||||||
Notes [3] - For Mumps: # Antigen-specific PPS, N=427, 212 (Groups 1 & 2) # Response rate based on Ab titre ≥10 ELISA Ab units/mL # Non-inferiority margin, -10%. |
|||||||||||||||||||||||||
Statistical analysis title |
Non-inferiority for Rubella | ||||||||||||||||||||||||
Statistical analysis description |
The estimates of the differences between Group 1 (ProQuad + Infanrix hexa) & Group 2 (ProQuad) response rates were calculated with their 2-sided 95% confidence interval (CI). If the lower bounds of the 95% CI were greater than the non-inferiority margin, it was concluded that Group 1 response rates were non-inferior to Group 2 response rates.
Statistical analysis was based on the Miettinen & Nurminen method with stratification by region.
Analysis was done on the Antigen-specific PPS.
|
||||||||||||||||||||||||
Comparison groups |
Group 1: ProQuad + Infanrix hexa v Group 2: ProQuad
|
||||||||||||||||||||||||
Number of subjects included in analysis |
646
|
||||||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||||||
Analysis type |
non-inferiority [4] | ||||||||||||||||||||||||
Method |
|||||||||||||||||||||||||
Parameter type |
Difference in percentage of subjects | ||||||||||||||||||||||||
Point estimate |
-1.2
|
||||||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||||||
level |
95% | ||||||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||||||
lower limit |
-3.19 | ||||||||||||||||||||||||
upper limit |
1.35 | ||||||||||||||||||||||||
Notes [4] - For Rubella: # Antigen-specific PPS, N=431, 215 (Groups 1 & 2) # Response rate based on Ab titre ≥10 IU/mL # Non-inferiority margin, -10%. |
|||||||||||||||||||||||||
Statistical analysis title |
Non-inferiority for Varicella | ||||||||||||||||||||||||
Statistical analysis description |
The estimates of the differences between Group 1 (ProQuad + Infanrix hexa) & Group 2 (ProQuad) response rates were calculated with their 2-sided 95% confidence interval (CI). If the lower bounds of the 95% CI were greater than the non-inferiority margin, it was concluded that Group 1 response rates were non-inferior to Group 2 response rates.
Statistical analysis was based on the Miettinen & Nurminen method with stratification by region.
Analysis was done on the Antigen-specific PPS.
|
||||||||||||||||||||||||
Comparison groups |
Group 1: ProQuad + Infanrix hexa v Group 2: ProQuad
|
||||||||||||||||||||||||
Number of subjects included in analysis |
646
|
||||||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||||||
Analysis type |
non-inferiority [5] | ||||||||||||||||||||||||
Method |
|||||||||||||||||||||||||
Parameter type |
Difference in percentage of subjects | ||||||||||||||||||||||||
Point estimate |
2.53
|
||||||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||||||
level |
95% | ||||||||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||||||||
lower limit |
-0.41 | ||||||||||||||||||||||||
upper limit |
6.58 | ||||||||||||||||||||||||
Notes [5] - For Varicella: # Antigen-specific PPS, N=394, 205 (Groups 1 & 2) # Response rate based on Ab titre ≥5 gpELISA units/mL # Non-inferiority margin, -10%. |
|
|||||||||||||||||||
End point title |
Antibody (Ab) response rates to Hepatitis B and Haemophilus influenzae type b (PRP) 6 weeks after Infanrix hexa booster dose, administered concomitantly or not with ProQuad dose 1 (Group 1 vs Group 3) [6] | ||||||||||||||||||
End point description |
Percentage of subjects with an Ab titre ≥10 IU/mL for Hepatitis B, and ≥1 µg/mL for Haemophilus influenzae type b (polyribosylribitol phosphate, PRP) 6 weeks after Infanrix hexa booster dose, administered concomitantly or not with ProQuad dose 1.
Ab titres were measured by enhanced chemiluminescence (ECi) assay for Hepatitis B and Farr-type radioimmunoassay for PRP.
Analysis was done on the Per Protocol Set (PPS), i.e. all randomised subjects excluding those with protocol violations which may interfere with the immunogenicity evaluation.
Note: (N=***, ***) represents the number of assessed subjects in the “ProQuad + Infanrix hexa” and “Infanrix hexa” groups, respectively.
|
||||||||||||||||||
End point type |
Primary
|
||||||||||||||||||
End point timeframe |
6 weeks after Infanrix hexa booster dose, administered concomitantly or not with ProQuad dose 1.
|
||||||||||||||||||
Notes [6] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: The objective of this endpoint was to evaluate the antibody response rates to Hepatitis B and Haemophilus influenzae type b (PRP) 6 weeks after Infanrix hexa booster dose, administered concomitantly or not with ProQuad dose 1. So this endpoint did not concern subjects of the "ProQuad" arm. |
|||||||||||||||||||
|
|||||||||||||||||||
Statistical analysis title |
Non-inferiority for Hepatitis B | ||||||||||||||||||
Statistical analysis description |
The estimates of the differences between Group 1 (ProQuad + Infanrix hexa) & Group 3 (Infanrix hexa) response rates were calculated with their 2-sided 95% confidence interval (CI). If the lower bounds of the 95% CI were greater than the non-inferiority margin, it was concluded that Group 1 response rates were non-inferior to Group 3 response rates.
Statistical analysis was based on the Miettinen & Nurminen method with stratification by region.
Analysis was done on the PPS.
|
||||||||||||||||||
Comparison groups |
Group 1: ProQuad + Infanrix hexa v Group 3: Infanrix hexa
|
||||||||||||||||||
Number of subjects included in analysis |
626
|
||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||
Analysis type |
non-inferiority [7] | ||||||||||||||||||
Method |
|||||||||||||||||||
Parameter type |
Difference in percentage of subjects | ||||||||||||||||||
Point estimate |
1.36
|
||||||||||||||||||
Confidence interval |
|||||||||||||||||||
level |
95% | ||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||
lower limit |
-0.29 | ||||||||||||||||||
upper limit |
4.24 | ||||||||||||||||||
Notes [7] - For Hepatitis B: # PPS, N=411, 215 (Groups 1 & 3) # Response rate based on Ab titre ≥10 IU/mL # Non-inferiority margin, -5%. |
|||||||||||||||||||
Statistical analysis title |
Non-inferiority for PRP | ||||||||||||||||||
Statistical analysis description |
The estimates of the differences between Group 1 (ProQuad + Infanrix hexa) & Group 3 (Infanrix hexa) response rates were calculated with their 2-sided 95% confidence interval (CI). If the lower bounds of the 95% CI were greater than the non-inferiority margin, it was concluded that Group 1 response rates were non-inferior to Group 3 response rates.
Statistical analysis was based on the Miettinen & Nurminen method with stratification by region.
Analysis was done on the PPS.
|
||||||||||||||||||
Comparison groups |
Group 1: ProQuad + Infanrix hexa v Group 3: Infanrix hexa
|
||||||||||||||||||
Number of subjects included in analysis |
626
|
||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||
Analysis type |
non-inferiority [8] | ||||||||||||||||||
Method |
|||||||||||||||||||
Parameter type |
Difference in percentage of subjects | ||||||||||||||||||
Point estimate |
2.97
|
||||||||||||||||||
Confidence interval |
|||||||||||||||||||
level |
95% | ||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||
lower limit |
0.17 | ||||||||||||||||||
upper limit |
6.89 | ||||||||||||||||||
Notes [8] - For PRP: # PPS, N=387, 211 (Groups 1 & 3) # Response rate based on Ab titre ≥1 µg/mL # Non-inferiority margin, -5%. |
|
||||||||||||||||||||||
End point title |
Geometric Mean Titres (GMT) for the 3 pertussis antigens (PT, FHA & PRN) 6 weeks after Infanrix hexa booster dose, administered concomitantly or not with ProQuad dose 1 (Group 1 vs Group 3) [9] | |||||||||||||||||||||
End point description |
Antibody titres expressed in EU/mL were measured for the 3 pertussis antigens (Pertussis toxoid (PT), Filamentous haemagglutinin (FHA) & Pertactin (PRN)) by Enzyme-Linked Immunosorbent Assay (ELISA) 6 weeks after Infanrix hexa booster dose, administered concomitantly or not with ProQuad dose 1.
Analysis was done on the Per Protocol Set (PPS), i.e. all randomised subjects excluding those with protocol violations which may interfere with the immunogenicity evaluation.
Note: (N=***, ***) represents the number of assessed subjects in the “ProQuad + Infanrix hexa” and “Infanrix hexa” groups, respectively.
|
|||||||||||||||||||||
End point type |
Primary
|
|||||||||||||||||||||
End point timeframe |
6 weeks after Infanrix hexa booster dose, administered concomitantly or not with ProQuad dose 1.
|
|||||||||||||||||||||
Notes [9] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: The objective of this endpoint was to evaluate the Geometric Mean Titres (GMT) for the 3 pertussis antigens (PT, FHA & PRN) 6 weeks after Infanrix hexa booster dose, administered concomitantly or not with ProQuad dose 1. So this endpoint did not concern subjects of the "ProQuad" arm. |
||||||||||||||||||||||
|
||||||||||||||||||||||
Statistical analysis title |
Non-inferiority for PT | |||||||||||||||||||||
Statistical analysis description |
The estimates of the post-vaccination GMT ratios Group 1 (ProQuad + Infanrix hexa) / Group 3 (Infanrix hexa) were calculated with their 2-sided 95% confidence interval (CI) and adjusted for pre-vaccination titres, Infanrix hexa primary vaccination & region. If the lower bounds of the 95% CI were greater than the non-inferiority margin, it was concluded that Group 1 GMT were non-inferior to Group 3 GMT.
Analysis was done on the PPS.
|
|||||||||||||||||||||
Comparison groups |
Group 3: Infanrix hexa v Group 1: ProQuad + Infanrix hexa
|
|||||||||||||||||||||
Number of subjects included in analysis |
597
|
|||||||||||||||||||||
Analysis specification |
Pre-specified
|
|||||||||||||||||||||
Analysis type |
non-inferiority [10] | |||||||||||||||||||||
Method |
||||||||||||||||||||||
Parameter type |
GMT ratio | |||||||||||||||||||||
Point estimate |
0.97
|
|||||||||||||||||||||
Confidence interval |
||||||||||||||||||||||
level |
95% | |||||||||||||||||||||
sides |
2-sided
|
|||||||||||||||||||||
lower limit |
0.88 | |||||||||||||||||||||
upper limit |
1.08 | |||||||||||||||||||||
Notes [10] - For PT: # PPS, N=379, 209 (Groups 1 & 3) # Non-inferiority margin, 0.5. Statistical analysis was based on an ANCOVA model with the log-transformed post-vaccination titres as response, the log-transformed baseline titres as covariate, the Infanrix hexa primary vaccination, the Region (nested effect) and the Group as fixed effects. |
||||||||||||||||||||||
Statistical analysis title |
Non-inferiority for FHA | |||||||||||||||||||||
Statistical analysis description |
The estimates of the post-vaccination GMT ratios Group 1 (ProQuad + Infanrix hexa) / Group 3 (Infanrix hexa) were calculated with their 2-sided 95% confidence interval (CI) and adjusted for pre-vaccination titres, Infanrix hexa primary vaccination & region. If the lower bounds of the 95% CI were greater than the non-inferiority margin, it was concluded that Group 1 GMT were non-inferior to Group 3 GMT.
Analysis was done on the PPS.
|
|||||||||||||||||||||
Comparison groups |
Group 1: ProQuad + Infanrix hexa v Group 3: Infanrix hexa
|
|||||||||||||||||||||
Number of subjects included in analysis |
597
|
|||||||||||||||||||||
Analysis specification |
Pre-specified
|
|||||||||||||||||||||
Analysis type |
non-inferiority [11] | |||||||||||||||||||||
Method |
||||||||||||||||||||||
Parameter type |
GMT ratio | |||||||||||||||||||||
Point estimate |
1.09
|
|||||||||||||||||||||
Confidence interval |
||||||||||||||||||||||
level |
95% | |||||||||||||||||||||
sides |
2-sided
|
|||||||||||||||||||||
lower limit |
0.98 | |||||||||||||||||||||
upper limit |
1.23 | |||||||||||||||||||||
Notes [11] - For FHA: # PPS, N=386, 211 (Groups 1 & 3) # Non-inferiority margin, 0.5. Statistical analysis was based on an ANCOVA model with the log-transformed post-vaccination titres as response, the log-transformed baseline titres as covariate, the Infanrix hexa primary vaccination, the Region (nested effect) and the Group as fixed effects. |
||||||||||||||||||||||
Statistical analysis title |
Non-inferiority for PRN | |||||||||||||||||||||
Statistical analysis description |
The estimates of the post-vaccination GMT ratios Group 1 (ProQuad + Infanrix hexa) / Group 3 (Infanrix hexa) were calculated with their 2-sided 95% confidence interval (CI) and adjusted for pre-vaccination titres, Infanrix hexa primary vaccination & region. If the lower bounds of the 95% CI were greater than the non-inferiority margin, it was concluded that Group 1 GMT were non-inferior to Group 3 GMT.
Analysis was done on the PPS.
|
|||||||||||||||||||||
Comparison groups |
Group 1: ProQuad + Infanrix hexa v Group 3: Infanrix hexa
|
|||||||||||||||||||||
Number of subjects included in analysis |
597
|
|||||||||||||||||||||
Analysis specification |
Pre-specified
|
|||||||||||||||||||||
Analysis type |
non-inferiority [12] | |||||||||||||||||||||
Method |
||||||||||||||||||||||
Parameter type |
GMT ratio | |||||||||||||||||||||
Point estimate |
1.18
|
|||||||||||||||||||||
Confidence interval |
||||||||||||||||||||||
level |
95% | |||||||||||||||||||||
sides |
2-sided
|
|||||||||||||||||||||
lower limit |
1.03 | |||||||||||||||||||||
upper limit |
1.36 | |||||||||||||||||||||
Notes [12] - For PRN: # PPS, N=385, 211 (Groups 1 & 3) # Non-inferiority margin, 0.5. Statistical analysis was based on an ANCOVA model with the log-transformed post-vaccination titres as response, the log-transformed baseline titres as covariate, the Infanrix hexa primary vaccination, the Region (nested effect) and the Group as fixed effects. |
|
|||||||||||||||||||||||||
End point title |
Geometric Mean Titres (GMT) for Measles, Mumps, Rubella, and Varicella 6 weeks after ProQuad dose 1, administered concomitantly or not with Infanrix hexa booster dose (Group 1 vs Group 2) [13] | ||||||||||||||||||||||||
End point description |
Antibody (Ab) titres were measured for Measles, Mumps & Rubella by ELISA, and for Varicella by gpELISA 6 weeks after ProQuad dose 1, administered concomitantly or not with Infanrix hexa booster dose.
Ab titres are expressed in ELISA mIU/mL for Measles, ELISA Ab units/mL for Mumps, IU/mL for Rubella, & gpELISA units /mL for Varicella.
Analysis was done on the Antigen-Specific Per Protocol Set (PPS), i.e. all randomised subjects initially seronegative for those antigens (Measles Ab titre <255 mIU/mL, Mumps Ab titre <10 ELISA Ab units/mL, Rubella Ab titre <10 IU/mL, and Varicella Ab titre <1.25 gpELISA units/mL) excluding subjects with protocol violations which may interfere with the immunogenicity evaluation.
Note: (N=***, ***) represents the number of assessed subjects in the “ProQuad + Infanrix hexa” and “ProQuad” groups, respectively.
|
||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||
End point timeframe |
6 weeks after ProQuad dose 1, administered concomitantly or not with Infanrix hexa booster dose.
|
||||||||||||||||||||||||
Notes [13] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: The objective of this endpoint was to evaluate the Geometric Mean Titres (GMT) for Measles, Mumps, Rubella, and Varicella 6 weeks after ProQuad dose 1, administered concomitantly or not with Infanrix hexa booster dose. So this endpoint did not concern subjects of the "Infanrix hexa" arm. |
|||||||||||||||||||||||||
|
|||||||||||||||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||
End point title |
Percentage of subjects with anti-Varicella antibody (Ab) titre ≥1.25 gpELISA units/mL 6 weeks after ProQuad dose 1, administered concomitantly or not with Infanrix hexa booster dose (Group 1 vs Group 2) [14] | |||||||||||||||
End point description |
Percentage of subjects with anti-Varicella Ab titre ≥1.25 gpELISA units/mL measured by glycoprotein ELISA (gpELISA) 6 weeks after ProQuad dose 1, administered concomitantly or not with Infanrix hexa booster dose.
Analysis was done on the Varicella-Specific Per Protocol Set (PPS), i.e. all randomised subjects initially seronegative for Varicella (Ab titre <1.25 gpELISA units/mL) excluding subjects with protocol violations which may interfere with the immunogenicity evaluation.
Note: (N=***, ***) represents the number of assessed subjects in the “ProQuad + Infanrix hexa” and “ProQuad” groups, respectively.
|
|||||||||||||||
End point type |
Secondary
|
|||||||||||||||
End point timeframe |
6 weeks after ProQuad dose 1, administered concomitantly or not with Infanrix hexa booster dose.
|
|||||||||||||||
Notes [14] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: The objective of this endpoint was to evaluate the of subjects with anti-Varicella antibody (Ab) titre ≥1.25 gpELISA units/mL 6 weeks after ProQuad dose 1, administered concomitantly or not with Infanrix hexa booster dose. So this endpoint did not concern subjects of the "Infanrix hexa" arm. |
||||||||||||||||
|
||||||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||||||||
End point title |
Antibody (Ab) response rates to Diphtheria, Tetanus, and Poliomyelitis types 1, 2 & 3, 6 weeks after Infanrix hexa booster dose, administered concomitantly or not with ProQuad dose 1 (Group 1 vs Group 3) [15] | |||||||||||||||||||||||||||
End point description |
Percentage of subjects with an Ab titre ≥0.1 IU/mL for Diphtheria & Tetanus, and ≥8 (1/dil) for Poliomyelitis types 1, 2 & 3, 6 weeks after Infanrix hexa booster dose, administered concomitantly or not with ProQuad dose 1.
Ab titres were measured by a toxin neutralization test for Diphtheria, by ELISA for Tetanus, and by seroneutralisation (SN) for Poliomyelitis types 1, 2 & 3.
Analysis was done on the Per Protocol Set (PPS), i.e. all randomised subjects excluding those with protocol violations which may interfere with the immunogenicity evaluation.
Note: (N=***, ***) represents the number of assessed subjects in the “ProQuad + Infanrix hexa” and “Infanrix hexa” groups, respectively.
|
|||||||||||||||||||||||||||
End point type |
Secondary
|
|||||||||||||||||||||||||||
End point timeframe |
6 weeks after Infanrix hexa booster dose, administered concomitantly or not with ProQuad dose 1.
|
|||||||||||||||||||||||||||
Notes [15] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: The objective of this endpoint was to evaluate the antibody response rates to Diphtheria, Tetanus, and Poliomyelitis types 1, 2 & 3, 6 weeks after Infanrix hexa booster dose, administered concomitantly or not with ProQuad dose 1. So this endpoint did not concern subjects of the "ProQuad" arm. |
||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||||||||||||||
End point title |
Geometric Mean Titres (GMT) for Diphtheria, Tetanus, Poliomyelitis types 1, 2 & 3, Hepatitis B and Haemophilus influenzae type b 6 weeks after Infanrix hexa booster dose, administered concomitantly or not with ProQuad dose 1 (Group 1 vs Group 3) [16] | |||||||||||||||||||||||||||||||||
End point description |
Antibody (Ab) titres were measured for Diphtheria by a toxin neutralization test, for Tetanus by ELISA, for Poliomyelitis types 1, 2 & 3 by SN, for Hepatitis B by ECi assay, and for Haemophilus influenzae type b (PRP) by Farr-type radioimmunoassay 6 weeks after Infanrix hexa booster dose, administered concomitantly or not with ProQuad dose 1.
Ab titres are expressed in IU/mL for Diphtheria & Tetanus, 1/dil for Poliomyelitis types 1, 2 & 3, mIU/mL for Hepatitis B, and µg/mL for PRP.
Analysis was done on the Per Protocol Set (PPS), i.e. all randomised subjects excluding those with protocol violations which may interfere with the immunogenicity evaluation.
Note: (N=***, ***) represents the number of assessed subjects in the “ProQuad + Infanrix hexa” and “Infanrix hexa” groups, respectively.
|
|||||||||||||||||||||||||||||||||
End point type |
Secondary
|
|||||||||||||||||||||||||||||||||
End point timeframe |
6 weeks after Infanrix hexa booster dose, administered concomitantly or not with ProQuad dose 1.
|
|||||||||||||||||||||||||||||||||
Notes [16] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: The objective of this endpoint was to evaluate the Geometric Mean Titres (GMT) for Diphtheria, Tetanus, Poliomyelitis types 1, 2 & 3, Hepatitis B and Haemophilus influenzae type b 6 weeks after Infanrix hexa booster dose, administered concomitantly or not with ProQuad dose 1. So this endpoint did not concern subjects of the "ProQuad" arm. |
||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||
End point title |
Antibody (Ab) response rates to the 3 pertussis antigens (PT, FHA & PRN) 6 weeks after Infanrix hexa booster dose, administered concomitantly or not with ProQuad dose 1 (Group 1 vs Group 3) [17] | |||||||||||||||||||||
End point description |
Percentage of subjects with pertussis Ab titres for the 3 pertussis antigens (Pertussis toxoid (PT), Filamentous haemagglutinin (FHA) & Pertactin (PRN)) ≥Lower Limit of Quantification (LLOQ) in subjects with baseline Ab titres <LLOQ, or with Ab titres equal or greater than the baseline titres in subjects with baseline Ab titres ≥LLOQ 6 weeks after Infanrix hexa booster dose, administered concomitantly or not with ProQuad dose 1.
Ab titres were measured by Enzyme-Linked Immunosorbent Assay (ELISA).
Analysis was done on the Per Protocol Set (PPS), i.e. all randomised subjects excluding those with protocol violations which may interfere with the immunogenicity evaluation.
Note: (N=***, ***) represents the number of assessed subjects in the "ProQuad + Infanrix hexa" and "Infanrix hexa" groups, respectively.
|
|||||||||||||||||||||
End point type |
Secondary
|
|||||||||||||||||||||
End point timeframe |
6 weeks after Infanrix hexa booster dose, administered concomitantly or not with ProQuad dose 1.
|
|||||||||||||||||||||
Notes [17] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: The objective of this endpoint was to evaluate the antibody response rates to the 3 pertussis antigens (PT, FHA & PRN) 6 weeks after Infanrix hexa booster dose, administered concomitantly or not with ProQuad dose 1. So this endpoint did not concern subjects of the "ProQuad" arm. |
||||||||||||||||||||||
|
||||||||||||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||
End point title |
Geometric Mean Titres Ratios (GMTR) for the 3 Pertussis antigens (PT, FHA & PRN) 6 weeks after Infanrix hexa booster dose, administered concomitantly or not with ProQuad dose 1 (Group 1 vs Group 3) [18] | |||||||||||||||||||||
End point description |
Study participants were blood sampled between Day -7 (D-7) and D0 before vaccination (pre-vaccination) and 6 weeks (D42 to D56) after Infanrix hexa booster dose, administered concomitantly or not with ProQuad dose 1 (post-vaccination).
Antibody (Ab) titres were measured by ELISA for the 3 Pertussis antigens (Pertussis toxoid (PT), Filamentous haemagglutinin (FHA) & Pertactin (PRN)).
Individual post- / pre-vaccination anti-Pertussis Ab titres ratios were calculated for the 3 Pertussis antigens (PT, FHA & PRN).
Analysis was done on the Per Protocol Set (PPS), i.e. all randomised subjects excluding those with protocol violations which may interfere with the immunogenicity evaluation.
Note: (N=***, ***) represents the number of assessed subjects in the "ProQuad + Infanrix hexa" and "Infanrix hexa" groups, respectively.
|
|||||||||||||||||||||
End point type |
Secondary
|
|||||||||||||||||||||
End point timeframe |
6 weeks after Infanrix hexa booster dose, administered concomitantly or not with ProQuad dose 1.
|
|||||||||||||||||||||
Notes [18] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: The objective of this endpoint was to evaluate the Geometric Mean Titres Ratios (GMTR) of individual post-/pre-vaccination anti-Pertussis antibody (Ab) titres for the 3 Pertussis antigens (PT, FHA & PRN) 6 weeks after Infanrix hexa booster dose, administered concomitantly or not with ProQuad dose 1. So this endpoint did not concern subjects of the "ProQuad" arm. |
||||||||||||||||||||||
|
||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point title |
Global summary of safety from D0 to D28 after vaccination with ProQuad dose 1 and Infanrix hexa booster dose, administered concomitantly or alone | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point description |
Adverse events (AEs) occurring after vaccination with ProQuad and Infanrix hexa, administered concomitantly or alone, were recorded as follows:
1/ From D0 to D4: solicited injection-site adverse reactions (ISRs: erythema, pain, and swelling).
2/ From D0 to D28: # unsolicited ISRs (including erythema, pain, and swelling from D5 to D28), # AEs of interest (a/ injection-site rashes of interest, b/ non-injection site rashes of interest (Measles-like rash, Rubella-like rash, Varicella-like rash and Herpes zoster-like rash), c/ Mumps-like illness), # rectal or equivalent temperature, and # unsolicited systemic AEs.
AEs at injection sites were always considered as related to ProQuad or Infanrix hexa vaccines (ISRs). The investigator had to assess whether systemic AEs were vaccine-related systemic AEs or not.
Analysis was done on the Safety Analysis Set, i.e. all subjects who received at least 1 of the study vaccine(s) and who had safety follow-up data.
Note: "0" means not applicable.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point timeframe |
From Day 0 (D0) to D28 after administration of ProQuad dose 1 and Infanrix hexa booster dose, administered concomitantly or alone.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||
End point title |
Solicited injection-site reactions (ISRs) to ProQuad from D0 to D4 after ProQuad dose 1, administered concomitantly or not with Infanrix hexa booster dose (Group 1 vs Group 2) [19] | |||||||||||||||||||||
End point description |
Solicited injection-site adverse reactions (ISRs) to ProQuad were recorded from D0 to D4 after ProQuad dose 1, administered concomitantly or not with Infanrix hexa booster dose.
AEs at ProQuad injection site were always considered as related to ProQuad (ISRs).
Percentage of subjects presenting at least once the considered ISRs are presented here.
Analysis was done on the Safety Analysis Set, i.e. all subjects who received at least 1 of the study vaccine(s) and who had safety follow-up data.
|
|||||||||||||||||||||
End point type |
Secondary
|
|||||||||||||||||||||
End point timeframe |
From Day 0 (D0) to D4 after ProQuad dose 1, administered concomitantly or not with Infanrix hexa booster dose.
|
|||||||||||||||||||||
Notes [19] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: The objective of this endpoint was to evaluate the solicited ISRs to ProQuad vaccine. So this endpoint did not include the "Infanrix hexa" arm. |
||||||||||||||||||||||
|
||||||||||||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||
End point title |
Solicited injection-site reactions (ISRs) to Infanrix hexa from D0 to D4 after Infanrix hexa booster dose, administered concomitantly or not with ProQuad dose 1 (Group 1 vs Group 3) [20] | |||||||||||||||||||||
End point description |
Solicited injection-site adverse reactions (ISRs) to Infanrix hexa were recorded from D0 to D4 after Infanrix hexa booster dose, administered concomitantly or not with ProQuad dose 1.
AEs at Infanrix hexa injection site were always considered as related to Infanrix hexa (ISRs).
Percentage of subjects presenting at least once the considered ISRs are presented here.
Analysis was done on the Safety Analysis Set, i.e. all subjects who received at least 1 of the study vaccine(s) and who had safety follow-up data.
|
|||||||||||||||||||||
End point type |
Secondary
|
|||||||||||||||||||||
End point timeframe |
From Day 0 (D0) to D4 after Infanrix hexa booster dose, administered concomitantly or not with ProQuad dose 1.
|
|||||||||||||||||||||
Notes [20] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: The objective of this endpoint was to evaluate the solicited ISRs to Infanrix hexa. So this endpoint did not include the "ProQuad" arm. |
||||||||||||||||||||||
|
||||||||||||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||||||||||||||||||||||||||
End point title |
Unsolicited injection-site reactions (ISRs) to ProQuad from D0 to D28 after ProQuad dose 1, administered concomitantly or not with Infanrix hexa booster dose (Group 1 vs Group 2) [21] | |||||||||||||||||||||||||||||||||||||||||||||
End point description |
Unsolicited injection-site adverse reactions (ISRs) to ProQuad occurring from D0 to D28, including erythema, pain, and swelling from D5 to D28 after ProQuad dose 1, administered concomitantly or not with Infanrix hexa booster dose, were reported.
AEs at ProQuad injection site were always considered as related to ProQuad (ISRs).
Percentage of subjects presenting at least once the considered ISRs are presented here.
Analysis was done on the Safety Analysis Set, i.e. all subjects who received at least 1 of the study vaccine(s) and who had safety follow-up data.
|
|||||||||||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
|||||||||||||||||||||||||||||||||||||||||||||
End point timeframe |
From Day 0 (D0) to D28 after ProQuad dose 1, administered concomitantly or not with Infanrix hexa booster dose.
|
|||||||||||||||||||||||||||||||||||||||||||||
Notes [21] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: The objective of this endpoint was to evaluate the unsolicited ISRs to ProQuad vaccine. So this endpoint did not include the "Infanrix hexa" arm. |
||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||||||||||||||||||||||||||
End point title |
Unsolicited injection-site reactions (ISRs) to Infanrix hexa from D0 to D28 after Infanrix hexa booster dose, administered concomitantly or not with ProQuad dose 1 (Group 1 vs Group 3) [22] | |||||||||||||||||||||||||||||||||||||||||||||
End point description |
Unsolicited injection-site adverse reactions (ISRs) to Infanrix hexa occurring from D0 to D28, including erythema, pain, and swelling from D5 to D28 after Infanrix hexa booster dose, administered concomitantly or not with ProQuad dose 1, were reported.
AEs at Infanrix hexa injection site were always considered as related to Infanrix hexa (ISRs).
Percentage of subjects presenting at least once the considered ISRs are presented here.
Analysis was done on the Safety Analysis Set, i.e. all subjects who received at least 1 of the study vaccine(s) and who had safety follow-up data.
|
|||||||||||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
|||||||||||||||||||||||||||||||||||||||||||||
End point timeframe |
From Day 0 (D0) to D28 after Infanrix hexa booster dose, administered concomitantly or not with ProQuad dose 1.
|
|||||||||||||||||||||||||||||||||||||||||||||
Notes [22] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: The objective of this endpoint was to evaluate the unsolicited ISRs to Infanrix hexa. So this endpoint did not include the "ProQuad" arm. |
||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||||||||
End point title |
Percentage of subjects reporting adverse events of interest from D0 to D28 after vaccination with ProQuad dose 1 and Infanrix hexa booster dose, administered concomitantly or alone | ||||||||||||||||||||||||||||||||||||||||||||
End point description |
Injection-site rashes of interest, non-injection site rashes of interest (Measles-like rash, Rubella-like rash, Varicella-like rash and Herpes zoster-like rash), and Mumps-like illness were reported from D0 to D28 after vaccination with ProQuad dose 1 and Infanrix hexa booster dose, administered concomitantly or alone.
Percentage of subjects presenting at least once the considered events are presented here.
Analysis was done on the Safety Analysis Set, i.e. all subjects who received at least 1 of the study vaccine(s) and who had safety follow-up data.
|
||||||||||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||||||||||||||||
End point timeframe |
From Day 0 (D0) to D28 after vaccination with ProQuad dose 1 and Infanrix hexa booster dose, administered concomitantly or alone.
|
||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
Unsolicited non-serious systemic adverse events (AEs) were collected from D0 to D28 following vaccination.
Serious AEs and deaths were collected throughout the study.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse event reporting additional description |
Analysis of AEs was performed on the Safety Analysis Set, i.e. all subjects who received at least 1 of the study vaccine(s) and who had safety follow-up data.
Unsolicited non-serious systemic AEs (vaccine-related or not) with incidence ≥1% in at least 1 reporting group are presented hereafter.
None of the serious AEs were vaccine-related.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Non-systematic | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
10.0
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Group 1: ProQuad + Infanrix hexa
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
# Subjects received ProQuad dose 1 by subcutaneous route concomitantly with Infanrix hexa (DTaP-HBV-IPV-Hib) booster dose by intramuscular route at 12-23 months of age. # Respectively, 332 (70.0%) subjects reported at least 1 non-serious unsolicited systemic AE, 152 (32.1%) subjects reported at least 1 ProQuad-related non-serious unsolicited systemic AE, and 100 (21.1%) subjects reported at least 1 Infanrix hexa-related non-serious unsolicited systemic AE within 28 days after ProQuad dose 1 administered concomitantly with Infanrix hexa booster dose. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Group 2: ProQuad
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
# Subjects received ProQuad dose 1 by subcutaneous route at 12-23 months of age. # Respectively, 152 (65.0%) subjects reported at least 1 non-serious unsolicited systemic AE, and 69 (29.5%) subjects reported at least 1 ProQuad-related non-serious unsolicited systemic AE within 28 days after ProQuad dose 1. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Group 3: Infanrix hexa
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
# Subjects received Infanrix hexa (DTaP-HBV-IPV-Hib) booster dose by intramuscular route at 12-23 months of age. # Respectively, 149 (62.3%) subjects reported at least 1 non-serious unsolicited systemic AE, and 40 (16.7%) subjects reported at least 1 Infanrix hexa-related non-serious unsolicited systemic AE within 28 days after Infanrix hexa booster dose. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 1% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? Yes | |||
Date |
Amendment |
||
12 Sep 2007 |
Update of study calendar due to the extension of the subject recruitment period, and the changes in the distribution of subjects between Germany and Italy (competitive recruitment) implemented to ensure the best recruitment rate and the achievement of the global targeted included population. (This change was not expected to impact the primary objective of the study since both Infanrix hexa primary vaccination schedules provide similar protection to the subjects. In addition, the statistical models include stratification by country.) |
||
26 Nov 2007 |
Further updated study calendar required in order to ensure the planned sample size, and the labelling of the new lot of ProQuad which was sourced from commercial product. |
||
11 Mar 2008 |
Changes implemented concerning polio testing (Vero cells replacing Hep-2 cells). |
||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported |